Every month, I select one or more stocks that I’ll be buying in real life for my Roth IRA. I’ve been doing this for over two years, and — not including dividends — these picks have returned 27%, which is beating the S&P 500 by almost 8 percentage points.
This month, I’m buying two stocks that have gone on great runs lately. Instead of backing out because I’ve anchored on the previous price of these stocks, I’m going to be putting my money behind their business momentum and innovation.
The first of these two stocks is Medidata Solutions Inc (NASDAQ:MDSO).
The process of bringing new medicines and medical devices to market can be a long and arduous one. There are research costs, randomized clinical trials, and many levels of Food and Drug Administration approvals that need to be navigated. Carried out over years, with millions of different products, this process can cost medical companies billions of dollars.
That’s where Medidata Solutions Inc (NASDAQ:MDSO) comes in. The company’s core product — Medidata Rave — is a cloud-based, software-as-a-service offering that helps to streamline the approval process and cut down on costs.
Rave, and its ancillary applications, specifically focuses on designing randomized studies, assisting trial protocols, optimizing resource allocation, capturing data electronically, and managing clinical trial data.
Can history repeat itself?
If you think about it, the progression of the medical approval process to a cloud-based solution makes sense.
It was 1999 when salesforce.com, inc. (NYSE:CRM) was founded, and now the company offers cloud-based solutions to businesses that focus on sales, service, and marketing strategies. Since the company went public, its shares have risen almost 1,000% and is now worth more than $25 billion.
CRM Total Return Price data by YCharts.
If, at any point in time, an investor would have been scared of strong price appreciation, he or she could have missed out on huge gains. Even a purchase made right before the Great Recession would have returned 150%, outpacing the S&P 500 by more than 100 percentage points. And since mid-2011, shares of salesforce.com, inc. (NYSE:CRM) have traded hands at more than 40 times earnings.
There are two things to learn from this. The first is that being a first-mover in the cloud while providing industry-specific software can be a runway for enormous growth potential. The second is that when dealing with fast-growers like this, it is sometimes more useful to evaluate how expensive a stock is by its market cap, rather than its price-to-earnings ratio.
While Medidata Solutions Inc (NASDAQ:MDSO) has also seen strong appreciation since its IPO — and it trades for about 72 times non-GAAP earnings — I think the company’s $2.3 billion valuation shows there’s still room for growth.
MDSO Total Return Price data by YCharts.
Why I’m buying
There are two key variables that, if they continue, will lead to brighter days for Medidata Solutions Inc (NASDAQ:MDSO) shareholders. The first is continued migration of pharmaceutical and other medical companies to Medidata’s Rave platform. Medidata already counts 20 of the top 25 global pharmaceutical companies among its clients, with Johnson & Johnson (NYSE:JNJ), Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY), and AstraZeneca plc (ADR) (NYSE:AZN) being the biggest three.
But a look at the full client list gives you the feeling that other companies are starting to see the value in using Medidata’s cloud software.
Source: SEC filings.
